Nama Insights

Quest Diagnostics (DGX)

Healthcare · Diagnostics Research · NYSE

S&P 500
Quest Diagnostics (DGX) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $28.21B, a trailing price-to-earnings ratio of 23.1 and a free-cash-flow yield of 4.7%. Over the most recent reported fiscal year, revenue grew 11.8% and free cash flow per share grew 49.5%. Nama's AI scorecard rates it Hold, 5.6 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Hold · 5.6/10
The sections balance. As of Nov 7, 2026.
Momentum
Leading · +28.6% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-1.3%
How far the last close sits under the highest price of the past five years.
Market cap$28.21B
Trailing P/E23.1
Price / book3.7
Price / sales2.4
FCF yield4.7%
Dividend yield1.4%
Gross margin33.1%
Operating margin14.6%
Net margin9.5%
Revenue growth (YoY)+11.8%
Revenue growth (3-yr annual)+3.7%
EPS growth (YoY)+10.4%
FCF/share growth (YoY)+49.5%
Beta0.5
ExchangeNYSE
SectorHealthcare
IndustryDiagnostics Research

DGX earnings

Next report: Feb 9, 2027 (Q4 2026, EPS estimate $2.68). Beat the EPS estimate in 4 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Oct 22, 2026 $3.00 $2.87 +4.5% $3.10B
Q2 2026 Jul 23, 2026 $3.12 $2.82 +10.6% $3.04B
Q1 2026 Apr 21, 2026 $2.50 $2.37 +5.5% $2.90B
Q4 2025 Feb 10, 2026 $2.42 $2.36 +2.5% $2.81B

DGX analyst price target

Median target $260.00 from 15 analysts, ranging $235.00 – $279.00.

Diagnostics Research peers

TickerCompanyMarket capP/E
TMO Thermo Fisher Scientific $257.42B 28.1
DHR Danaher $161.86B 27.6
IDXX IDEXX Laboratories $53.26B 45.6
A Agilent Technologies $49.28B 28.8
WAT Waters $44.93B 31.8
IQV IQVIA $44.80B 21.2
NTRA Natera $44.78B —
MTD Mettler-Toledo International $34.51B 37.2
Explore live DGX data on Nama Insights →

Recent Congressional trades

Quest Diagnostics trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Carol Devine Miller House Sell $15,001 - $50,000 Aug 13, 2026
Julie Johnson House Sell $1,001 - $15,000 Aug 5, 2026
Alan Armstrong Senate Buy $1,001 - $15,000 Jul 21, 2026
Alan Armstrong Senate Buy $1,001 - $15,000 Jul 21, 2026
Julia Letlow House Sell $1,001 - $15,000 Jan 13, 2026
Julia Letlow House Buy $1,001 - $15,000 Jan 13, 2026
Julie Johnson House Sell $1,001 - $15,000 Dec 11, 2025
Carol Devine Miller House Sell $1,001 - $15,000 Apr 11, 2025
Earl Blumenauer House Sell $1,001 - $15,000 May 4, 2024
Thomas R Carper Senate Buy $1,001 - $15,000 —

DGX FAQ

Is DGX a buy?
Nama's AI scorecard currently rates Quest Diagnostics Hold (5.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is DGX's P/E ratio?
Quest Diagnostics trades at a trailing price-to-earnings ratio of 23.1.
When does DGX report earnings?
Quest Diagnostics's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $2.68.
What is the DGX price target?
The median analyst price target from 15 analysts is $260.00, with a range of $235.00 – $279.00.
Is DGX Shariah compliant?
Nama's AAOIFI-style screen reads Quest Diagnostics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does DGX pay a dividend?
Yes — Quest Diagnostics's dividend yield is 1.4%.

See more: Healthcare stocks →